natgillin/translations-raw huggingface dataset:
The co-administration of saxagliptin and CYP3A4/5 inducers, other than rifampicin (such as carbamazepine, dexamethasone, phenobarbital and phenytoin) has not been studied and may result in decreased plasma concentration of saxagliptin and increased concentration of its major metabolite.
Istodobna primjena saksagliptina s induktorima CYP3A4/5 osim rifampicina (kao što su karbamazepin, deksametazon, fenobarbital i fenitoin) nije se ispitivala, a mogla bi sniziti koncentracije saksagliptina te povisiti koncentracije njegova glavnog metabolita u plazmi.
The co-administration of saxagliptin and metformin has been studied in patients with type 2 diabetes inadequately controlled on metformin alone and in treatment-naive patients inadequately controlled on diet and exercise alone.
Istodobna primjena saksagliptina i metformina ispitana je u bolesnika sa šećernom bolešću tipa 2 u kojih glikemija nije bila odgovarajuće kontrolirana monoterapijom metforminom te u prethodno neliječenih bolesnika u kojih glikemija nije bila odgovarajuće kontrolirana samo dijetom i tjelovježbom.
The co-administration of sodium oxybate (6 g per day) with valproate (1250 mg per day) resulted in an increase in systemic exposure to sodium oxybate by approximately 25% and no significant change in Cmax.
Istodobna primjena natrijeva oksibata (6 g na dan) s valproatom (1250 mg na dan) dovela je do povećanja u sistemskoj izloženosti natrijevu oksibatu za približno 25% i neznačajnom promjenom u Cmax.
The co-administration of stavudine with REYATAZ is not expected to significantly alter the exposure of stavudine.
Ne očekuje se da će istovremena primjena stavudina i lijeka REYATAZ značajno promijeniti izloženost stavudinu.
The co-administration of trivalent Fluenz with the live attenuated vaccines: measles, mumps, rubella, varicella, and orally-administered poliovirus has been studied.
Ispitana je istodobna primjena trovalentnog cjepiva Fluenz sa živim atenuiranim cjepivima protiv ospica, zaušnjaka, rubele, varičele te peroralno primijenjenim poliovirusom.
The co-primary efficacy endpoints of the study were progression-free survival (PFS) as assessed by an independent review committee (IRC) and overall survival (OS) (see Table 8 and Figures 1 to 2).
Dva primarna ishoda ispitivanja za djelotvornost bila su preživljenje bez progresije bolesti (eng. progression-free survival, PFS) prema procjeni neovisnog ocjenjivačkog povjerenstva (engl. independent review committee, IRC) te ukupno preživljenje (engl. overall survival, OS) (vidjeti Tablicu 8 i Slike 1 i 2).
The co-primary efficacy endpoints were (1) change from baseline to end of treatment in mean number of incontinence episodes per 24 hours and (2) change from baseline to end of treatment in mean number of micturitions per 24 hours based on a 3-day micturition diary.
Višestruki primarni ishodi djelotvornosti bili su (1) promjena od početne vrijednosti do kraja liječenja u srednjoj vrijednosti broja epizoda inkontinencije tijekom 24 sata, te (2) promjena od početne vrijednosti do kraja liječenja u srednjoj vrijednosti broja mikcija tijekom 24 sata, na temelju voĎenja dnevnika mikcije kroz 3 dana.
The co-primary endpoint was seroconversion rate (anti JEV antibody titer ≥1:10) and geometric mean titers (GMT) at Day 56 as assessed by a Plaque Reduction Neutralization Test (PRNT) for the entire study population.
Ko-primarni ishod bila je stopa serokonverzije (titar anti-JEV protutijela ≥ 1:10) i geometrijska sredina titra (GMT, od engl Geometric Mean Titer), 56. dana, procijenjeno testom neutralizacije redukcije plaka (PRNT) za cijelu ispitivanu populaciju.
The co-primary endpoints for the efficacy analysis were:
Primarne mjere ishoda za analizu djelotvornosti bile su:
The co-primary endpoints in the placebo and active-controlled studies were the proportion of patients who achieved a PASI 75 response and IGA mod 2011 “clear” or “almost clear” response versus placebo at Week 12 (see Tables 2 and 3).
Ko-primarne mjere ishoda u placebom i aktivno kontroliranim ispitivanjima bile su udjeli bolesnika koji su postigli odgovor PASI 75 i IGA mod 2011 odgovor „čista“ ili „gotovo čista“ u usporedbi s placebom u 12. tjednu (vidjeti Tablice 2 i 3).
The co-primary outcome measures were progression-free survival and OS.
Koprimarne mjere ishoda bile su preživljenje bez progresije bolesti i OS.
The co-primary safety endpoints were discontinuation due to an adverse event and confirmed increase in serum creatinine ≥ 0.5 mg/dl or confirmed serum phosphate of < 2 mg/dl.
Ko-primarne mjere ishoda za sigurnost bile su prekid liječenja zbog nuspojave i potvrđenog porasta kreatinina u serumu za ≥ 0.5 mg/dl ili potvrđeni fosfat u serumu < 2 mg/dl.
The coadministration of dapagliflozin and metformin has been studied in subjects with type 2 diabetes inadequately controlled on metformin alone or in combination with a DPP-4 inhibitor (sitagliptin), sulphonylurea or insulin.
Istodobna primjena dapagliflozina i metformina ispitana je u ispitanika sa šećernom bolešću tipa 2 u kojih glikemija nije bila dovoljno dobro regulirana metforminom samim ili u kombinaciji s inhibitorom DPP-4 (sitagliptinom), sulfoniurejom ili inzulinom.
The coadministration of riociguat with Kaletra is not recommended (see section 4.4 and refer to riociguat SmPC).
Istodobna primjena riocigvata i lijeka Kaletra se ne preporučuje (vidjeti dio 4.4 i Sažetak opisa svojstava lijeka za riocigvat).
The coadministration of riociguat with Norvir is not recommended (see section 4.4 and refer to riociguat SmPC).
Istodobna primjena riocigvata i lijeka Norvir se ne preporučuje (vidjeti dio 4.4 i Sažetak opisa svojstava lijeka za riocigvat).
The coadministration of saxagliptin and metformin has been studied in patients with type 2 diabetes inadequately controlled on metformin alone and in treatment-naive patients inadequately controlled on diet and exercise alone.
Istodobna primjena saksagliptina i metformina ispitana je u bolesnika sa šećernom bolešću tipa 2 u kojih glikemija nije bila odgovarajuće kontrolirana monoterapijom metforminom te u prethodno neliječenih bolesnika u kojih glikemija nije bila odgovarajuće kontrolirana samo dijetom i tjelovježbom.
The coadministration of vorapaxar with Kaletra is not recommended (see section 4.4 and refer to the vorapaxar SmPC).
Istodobna primjena vorapaksara i lijeka Kaletra se ne preporučuje (vidjeti dio 4.4 i Sažetak opisa svojstava lijeka za vorapaksar).
The coadministration of vorapaxar with Norvir is not recommended (see section 4.4 and refer to the vorapaxar SmPC).
Istodobna primjena vorapaksara i lijeka Norvir se ne preporučuje (vidjeti dio 4.4 i Sažetak opisa svojstava lijeka za vorapaksar).
The coadministration of Zontivity with anticoagulants e.g., warfarin and new oral anticoagulants (NOACs), should be avoided. (See section 4.4.)
Treba izbjegavati istodobnu primjenu lijeka Zontivity s antikoagulansima, npr. varfarinom i novim peroralnim antikoagulansima (vidjeti dio 4.4.).
The collective analysis of preclinical and clinical irritation studies for the orodispersible tablet indicate that this formulation in unlikely to pose risk for local irritation with clinical use.
Skupna analiza nekliničkih i kliničkih ispitivanja iritacije kod primjene raspadljivih tableta za usta pokazuje da nije vjerojatno da bi ova formulacija izazvala lokalnu iritaciju u kliničkoj primjeni.
The colour indicator of most CO2 absorbents does not necessarily change as a result of desiccation.
Boja indikatora i većine apsorbera CO2 ne mijenja se nužno kao rezultat sušenja.
The colour of the solution can vary from clear to pale yellow or light brown.
Boja otopine može biti od bezbojne preko svijetložute do svijetlosmeđe.
The colour of the solution can vary from clear to pale yellow up to light brown.
Boje otopine može biti od bezbojne preko svijetložute do svijetlosmeđe.
The combination (4:1) of buprenorphine hydrochloride and naloxone hydrochloride was not mutagenic in a bacterial mutation assay (Ames test), and was not clastogenic in an in vitro cytogenetic assay in human lymphocytes or in an intravenous micronucleus test in the rat.
Kombinacija (4:1) buprenorfinklorida i naloksonklorida nije imala mutagene učinke u ispitivanju mutagenosti na bakterijama (Amesov test) i nije bila klastogenična u citogenetičkom ispitivanju in vitro na ljudskim limfocitima ili u intravenskom mikronukleusnom testu u štakora.
The combination Enbrel and anakinra has not demonstrated increased clinical benefit and is therefore not recommended.
Nije dokazano da kombinacija Enbrela i anakinre povećava kliničku korist te se stoga ne preporučuje.
The combination is not recommended.
Kombinacija se ne preporuča.
The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Upozorava se na pojačano praćenje nuspojava povezanih s rifabutinom uključujući neutropeniju i uveitis zbog povećane izloženosti rifabutinu.
The combination of
Kombinacija INTELENCEa
The combination of
Kombinaciju
The combination of 300 mg irbesartan and 12.5 mg hydrochlorothiazide resulted in an overall placebo-subtracted systolic/diastolic reductions of up to 13.6/11.5 mm Hg.
12,5 mg hidroklorotiazida dovela je do sveukupnog sniženja sistoličkog/dijastoličkog krvnog tlaka korigiranog za placebo za 13,6/11,5 mm Hg.
The combination of avanafil and
Kombinacija avanafila i lijeka
The combination of avanafil and boosted PREZISTA is contraindicated (see section 4.3).
PREZISTE je kontraindicirana (vidjeti
The combination of bosentan and epoprostenol has been investigated in two studies: AC-052-355 (BREATHE-2) and AC-052-356 (BREATHE-3).
Kombinacija bosentana i epoprostenola ispitana je u sklopu dvije studije: AC-052-355 (BREATHE-2) i AC-052-356 (BREATHE-3).
The combination of Ceplene and interleukin-2 was more effective than no treatment in increasing the time until AML came back or the patient died: in the patients in their first complete remission, the average time without disease increased from 291 days with no treatment to 450 days after treatment with Ceplene and interleukin-2.
Kombinacija lijekova Ceplene i interleukin-2 bila je djelotvornija nego da se terapija ne primjenjuje u slučajevima produljivanja razdoblja do ponovnog pojavljivanja AML-a ili smrti bolesnika: u bolesnika u njihovoj prvoj potpunoj remisiji, prosječno vrijeme bez bolesti produljilo se s 291 dana kada nije uzimana terapija na 450 dana nakon terapije lijekovima Ceplene i interleukin-2.
The combination of clopidogrel/acetylsalicylic acid is not recommended in this population.
Ne preporučuje se kombinacija klopidogrela i acetilsalicilatne kiseline u toj populaciji.
The combination of clopidogrel/acetylsalicylic acid must not be used in patients with severe renal impairment (see section 4.3).
Kombinacija klopidogrela i acetilsalicilatne kiseline ne smije se primjenjivati u bolesnika s teškim oštećenjem funkcijoe bubrega (vidjeti dio 4.3).
The combination of clopidogrel/acetylsalicylic acid must not be used in patients with severe renal impairment (see section 4.3).
Kombinacija klopidogrela i acetilslicilatne kiseline ne smije se primjenjivati u bolesnika s teškim oštećenjem funkcije bubrega (vidjeti dio 4.3).
The combination of dabrafenib with trametinib has shown anti- tumour activity in BRAF V600 mutation positive melanoma cell lines in vitro and delays the emergence of resistance in vivo in BRAF V600 mutation positive melanoma xenografts.
Kombinacija dabrafeniba s trametinibom je pokazala antitumorsku aktivnost u staničnim linijama melanoma pozitivnog na mutaciju BRAF V600 in vitro i odgađa pojavu rezistencije u ksenograftima s melanomom pozitivnim na mutaciju BRAF V600 in vivo.
The combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate has been studied in 460 patients either as the fixed-dose combination tablet Atripla (study AI266073) or as the component products (study GS-01-934).
Kombinacija efavirenza, emtricitabina i tenofovirdizoproksilfumarata ispitivana je u 460 pacijenata koji su primali tabletu Atriple s kombinacijom fiksnih doza (ispitivanje AI266073) ili lijekove s pojedinačnom komponentom (ispitivanje GS-01-934).
the combination of elvitegravir
elvitegravira i tipranavira (vidjeti
the combination of elvitegravir
ne preporučuje se kombinacija
The combination of emtricitabine, rilpivirine and tenofovir disoproxil fumarate has been studied as the component products in treatment-naïve patients (Phase III studies C209 and C215).
Kombinacija emtricitabina, rilpivirina i tenofovirdizoproksilfumarata ispitana je njihovom primjenom kao zasebnih lijekova u pacijenata koji prethodno nisu bili liječeni (III. faza ispitivanja C209 i C215).
The combination of Entresto with an ACE inhibitor is contraindicated due to the increased risk of angioedema (see section 4.3).
Kombinacija Entresta s ACE inhibitorom kontraindicirana je zbog povećanog rizika od angioedema (vidjeti dio 4.3).
The combination of Entresto with direct renin inhibitors such as aliskiren is not recommended (see section 4.5).
Kombinacija Entresta s direktnim inhibitorima renina kao što je aliskiren nije preporučljiva (vidjeti dio 4.5).
The combination of Eviplera and H2-receptor antagonists should be used with particular caution as co-administration may cause significant decreases in rilpivirine plasma concentrations (reduced absorption, increase in gastric pH).
Kombinaciju lijeka Eviplera i antagonista H2-receptora treba primjenjivati s osobitim oprezom, jer istovremena primjena može prouzročiti značajno smanjenje koncentracije rilpivirina u plazmi (smanjena apsorpcija, povišenje želučanog pH).
The combination of FORTEKOR PLUS and other anti-hypertensive agents (e.g. calcium channel blockers, -blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects.
Kombinacija FORTEKORA PLUS i drugih antihipertenziva (npr. blokatora kalcijevih kanala, β- blokatora ili diuretika), anestetika ili sedativa može uzrokovati dodatne hipotenzivne učinke.
The combination of Humira and abatacept is not recommended (see section 4.4 “Concurrent administration of biologic DMARDS or TNF-antagonists”).
Kombinirana terapija lijekom Humira i abataceptom se ne preporučuje (vidjeti dio 4.4 “ Istodobna primjena bioloških antireumatika koji modificiraju tijek bolesti ili antagonista TNF-a“).
The combination of Inflectra and abatacept is not recommended.
Ne preporučuje se kombinirana primjena lijeka Inflectra i abatacepta.
The combination of INTELENCE and ribavirin can be used without dose adjustments.
treba primjenjivati s oprezom
The combination of Invirase with ritonavir was assessed in 656 patients in two studies that compared Invirase with indinavir and with lopinavir (other antiviral medicines), both in combination with ritonavir and other antiviral medicines.
Liječenje kombinacijom lijeka Invirase s ritonavirom ispitano je na 656 bolesnika u dvama ispitivanjima u okviru kojih je lijek Invirase uspoređivan s indinavirom te s lopinavirom (drugim antivirusnim lijekovima), u oba slučaja u kombinaciji s ritonavirom i drugim antivirusnim lijekovima.
The combination of irbesartan and hydrochlorothiazide has been rarely associated with symptomatic hypotension in hypertensive patients without other risk factors for hypotension.
Kombinacija irbesartana i hidroklorotiazida rijetko je povezana sa simptomatskom hipotenzijom u hipertenzivnih bolesnika koji nemaju druge rizične faktore koji bi uzrokovali hipotenziju.
The combination of ivabradine 10 mg twice daily with St John’s Wort was shown to reduce ivabradine AUC by half.
Pokazalo se da se kombinacijom ivabradina u dozi od 10 mg dva puta na dan s Gospinom travom, AUC ivabradina smanjuje za pola.
The combination of Kaletra with atorvastatin is not recommended.
Istodobna primjena lijeka Kaletra s atorvastatinom se ne preporučuje.
The combination of Kaletra with:
Kombinacija lijeka Kaletra sa:
The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated patients).
Kombinacija lenalidomida s deksametazonom u bolesnika s multiplim mijelomom povezana je s višom incidencijom neutropenije 3. i 4. stupnja (9,9%, odnosno 1,4% u bolesnika liječenih lenalidomidom/deksametazonom u usporedbi s 2,3% i 0,0% u bolesnika koji su primali placebo/deksametazon).
The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated patients; see section 4.8).
Kombinacija lenalidomida s deksametazonom u bolesnika s multiplim mijelomom povezana je s višom incidencijom trombocitopenije 3. i 4. stupnja (9,9%, odnosno 1,4% u bolesnika liječenih lenalidomidom/deksametazonom u usporedbi s 2,3% i 0,0% u bolesnika koji su primali placebo/deksametazon; vidjeti dio 4.8).
The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated patients; see section 4.8).
Kombinacija lenalidomida s deksametazonom u bolesnika s multiplim mijelomom povezana je s višom incidencijom trombocitopenije 3. i 4. stupnja (9,9%, odnosno, 1,4% u bolesnika liječenih lenalidomidom/deksametazonom u usporedbi s 2,3% i 0,0% u bolesnika koji su primali placebo/deksametazon, vidjeti dio 4.8).
The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared with 0.6% in placebo/dexamethasone-treated patients).
Kombinacija lenalidomida s deksametazonom u bolesnika s multiplim mijelomom povezana je s višom incidencijom neutropenije 4. stupnja (5,1% u bolesnika liječenih lenalidomidom/deksametazonom u usporedbi s 0,6% u bolesnika koji su primali placebo/deksametazon).
The combination of lenalidomide with dexamethasone in multiple myeloma patients with at least one prior therapy is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone- treated patients compared with 0.6% in placebo/dexamethasone-treated patients; see section 4.8).
Kombinacija lenalidomida s deksametazonom u bolesnika s multiplim mijelomom i najmanje jednom prethodnom terapijom povezana je s višom incidencijom neutropenije 4. stupnja (5,1% u bolesnika liječenih lenalidomidom/deksametazonom u usporedbi s 0,6% bolesnika koji su primali placebo/deksametazon; vidjeti dio 4.8).
The combination of lenalidomide with low dose dexamethasone in newly diagnosed multiple myeloma patients is associated with a decreased incidence of grade 3 and 4 thrombocytopenia (8.1 in Rd and Rd18 compared to 11% in MPT).
Kombinacija lenalidomida s niskom dozom deksametazona u bolesnika s novodijagnosticiranim multiplim mijelomom povezana je sa smanjenom incidencijom trombocitopenije 3. i 4. stupnja (8,1 u Rd i Rd18 u usporedbi s 11% u MPT).
The combination of lenalidomide with low dose dexamethasone in newly diagnosed multiple myeloma patients is associated with a decreased incidence of grade 4 neutropenia (8.5% in Rd and Rd18, compared with 15% in MPT).
Kombinacija lenalidomida s niskom dozom deksametazona u bolesnika s novodijagnosticiranim multiplim mijelomom povezana je sa smanjenom incidencijom neutropenije 4. stupnja (8,5% za Rd i Rd18, u usporedbi s 15% za MPT).
The combination of lenalidomide with melphalan and prednisone in clinical trials of newly diagnosed multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (34.1% in melphalan, prednisone and lenalidomide arm followed by lenalidomide [MPR+R] and melphalan, prednisone and lenalidomide followed by placebo [MPR+p] treated patients compared with 7.8% in MPp+p-treated patients; see section 4.8).
Kombinacija lenalidomida s melfalanom i prednizonom u kliničkim ispitivanjima bolesnika s novodijagnosticiranim multiplim mijelomom povezana je s većom incidencijom neutropenije 4. stupnja (34,1% u skupini bolesnika liječenih melfalanom, prednizonom i lenalidomidom, iza čega je slijedio lenalidomid [MPR+R] i bolesnika liječenih melfalanom, prednizonom i lenalidomidom iza čega je slijedio placebo [MPR+p] u usporedbi sa 7,8% bolesnika liječenih MPp+p; vidjeti dio 4.8).
The combination of lenalidomide with melphalan and prednisone in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (40.4% in MPR+R/MPR+p treated patients, compared with 13.7% in MPp+p-treated patients; see section 4.8).
Kombinacija lenalidomida s melfalanom i prednizonom u bolesnika s multiplim mijelomom povezana je s većom incidencijom trombocitopenije 3. stupnja i 4. stupnja (40,4% u bolesnika liječenih kombinacijom MPR+R/MPR+p u usporedbi s 13,7% u bolesnika liječenih s MPp+p; vidjeti dio 4.8).
The combination of lenalidomide with melphalan and prednisone in newly diagnosed multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (40.4% in MPR+R/MPR+p treated patients, compared with 13.7% in MPp+p-treated patients).
Kombinacija lenalidomida s melfalanom i prednizonom u bolesnika s novodijagnosticiranim multiplim mijelomom povezana je s većom incidencijom trombocitopenije 3. i 4. stupnja (40,4% u bolesnika liječenih kombinacijom MPR+R/MPR+p u usporedbi s 13,7% bolesnika liječenih s MPp+p).
The combination of lenalidomide with melphalan and prednisone in newly diagnosed multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (34.1% in MPR+R/MPR+p compared with 7.8% in MPp+p).
Kombinacija lenalidomida s melfalanom i prednizonom u bolesnika s novodijagnosticiranim multiplim mijelomom povezana je s većom incidencijom neutropenije 4. stupnja (34,1% za MPR+R/MPR+p usporedbi sa 7,8% za MPp+p).
The combination of levodopa and carbidopa is used in other medicines for Parkinson’s disease.
Kombinacija levodopa i karbidopa koristi se i u drugim lijekovima za liječenje Parkinsonove bolesti.
The combination of linagliptin and metformin when administered in combination with insulin may be associated with an increased risk of hepatic events.
Kada se kombinacija linagliptina i metformina primjenjuje zajedno s inzulinom ona može biti povezana s povećanim rizikom od nuspojava jetre.
The combination of lithium and Ifirmacombi is not recommended (see section 4.5).
Ne preporučuje se kombinacija litija i lijeka Ifirmacombi (vidjeti dio 4.5).
The combination of lithium and Ifirmasta is not recommended (see section 4.5).
Ne preporučuje se kombinacija litija i Ifirmaste (vidjeti dio 4.5).
The combination of lithium and irbesartan is not recommended (see section 4.5).
Ne preporučuje se kombinacija litija i irbesartana (vidjeti dio 4.5.).
The combination of lithium and Irbesartan/Hydrochlorothiazide Teva is not recommended (see section 4.5).
Ne preporučuje se kombinacija litija i lijeka Irbesartan/Hidroklorotiazid Teva (vidjeti dio 4.5).
The combination of lopinavir/ritonavir with atorvastatin is not recommended.
lopinavira/ritonavira i sildenafila je
The combination of lopinavir/ritonavir with:
Kombinacija lopinavira/ritonavira s:
The combination of macitentan with strong CYP3A4 inducers (e.g., rifampicin, St. John’s wort, carbamazepine, and phenytoin) should be avoided (see section 4.5).
Kombinaciju macitentana s jakim induktorima CYP3A4 (primjerice, s rifampicinom, gospinom travom, karbamazepinom i fenitoinom) treba izbjegavati (vidjeti dio 4.5).
The combination of macitentan with strong CYP3A4 inducers should be avoided (see section 4.4).
Kombinaciju macitentana s jakim induktorima CYP3A4 treba izbjegavati (vidjeti dio 4.4).